Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. In its latest filing, the company also replaced sole bookrunner Spartan Capital Securities with Revere Securities, and...read more
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. The Jupiter, FL-based company now plans to raise $15 million by offering 2.6 million shares at $5.75. The company had...read more
Following the year's largest IPO to date (CRBG), four small deals may price in the week ahead, only two of which are large enough to be included in our IPO stats. Neuro-inflammation biotech Jupiter Neurosciences (JUNS) plans to raise $15...read more
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Tuesday. In its latest filing, the company also replaced joint bookrunners Roth Capital and Dawson James with Spartan Securities...read more
Neuro-inflammation biotech Jupiter Neurosciences revives $12 million IPO with revised terms
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. In its latest filing, the company also replaced sole bookrunner Spartan Capital Securities with Revere Securities, and...read more
Neuro-inflammation biotech Jupiter Neurosciences revises terms ahead of $15 million IPO
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Friday. The Jupiter, FL-based company now plans to raise $15 million by offering 2.6 million shares at $5.75. The company had...read more
US IPO Week Ahead: The IPO calendar returns to small deals
Following the year's largest IPO to date (CRBG), four small deals may price in the week ahead, only two of which are large enough to be included in our IPO stats. Neuro-inflammation biotech Jupiter Neurosciences (JUNS) plans to raise $15...read more
Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Tuesday. In its latest filing, the company also replaced joint bookrunners Roth Capital and Dawson James with Spartan Securities...read more